Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer.
Klotz L, Pavlovich CP, Chin J, Hatiboglu G, Koch M, Penson D, Raman S, Oto A, Fütterer J, Serrallach M, Relle J, Lotan Y, Heidenreich A, Bonekamp D, Haider M, Tirkes T, Arora S, Macura KJ, Costa DN, Persigehl T, Pantuck AJ, Bomers J, Burtnyk M, Staruch R, Eggener S. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. Journal Of Urology 2020, 205: 769-779. PMID: 33021440, DOI: 10.1097/ju.0000000000001362.Peer-Reviewed Original ResearchConceptsGrade Group 2 diseaseProstate-specific antigen reductionGrade group 2Whole gland ablationTransurethral ultrasound ablationAntigen reductionMagnetic resonance imagingProstate cancerGroup 2Gland ablationMagnetic resonance imaging-guided transurethral ultrasound ablationGrade 3 adverse eventsResonance imagingTarget volumeEvidence of cancerUltrasound ablationIntermediate-risk diseaseRisk prostate cancerProspective multicenter trialMedian prostate volumeLocalized prostate cancerMedian treatment delivery timeTreatment delivery timeMagnetic resonancePrimary endpoint